The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Distribution Update

27 Jun 2005 06:00

Embargoed: 27 June 2004 Akers Biosciences, Inc. ("Akers" or the "Company") Re. UK Distribution Agreement Akers Biosciences, Inc. is pleased to announce the launch of a number of itsproducts in the UK through its UK distribution agent Advanced Rapid DiagnosticsLimited ("ARD"). ARD was established in order to penetrate the UK markets withAkers' growing range of products.The Company is already actively marketing a number of CE approved products inthe UK through ARD which, among others, include:Tests for `drugs of abuse'Akers has developed a suite of tests for `drugs of abuse' including tests foruse of methadone, heroine, cocaine, marijuana and ecstasy among others. Forthis product ARD is targeting the public service markets alongside retailbusinesses or, indeed, any organisation wishing to have the ability to performrapid tests on staff. The Company believes that there is significant potentialfor law enforcement agencies or educational establishments to adopt thesetests.Alcohol BreathalyzersARD is marketing Akers' range of alcohol breathalyzers in the UK to a range ofindustries, in particular transport businesses operating any form of vehicles,be they rail, air, road or sea. In addition to ensuring transportation safety,the use of these products may also positively impact insurance costs for thesebusinesses. ARD will also be looking to penetrate retail markets including highstreet pharmacies so that the public will have access to affordable tests toshow alcohol levels, with particular emphasis on self-regulation in the case ofdriving.PIFA‚® Heparin/PF4 test for heparin-induced thrombocytopenia and thrombosissyndrome (HITTS)Following increasing levels of penetration in the United States and Canada forthis test, the first rapid test for heparin/platelet factor-4 antibodies, ARDwill be initially targeting the private healthcare sector in the UK. Heparin isa widely used intravenous anticoagulant in the United Kingdom. Intravenousheparin is commonly used for the prophylaxis and treatment of thromboembolicdisease, as well as numerous other applications including certain types of lungand heart disorders, and during or after a variety of surgeries including openheart, bypass, dialysis and orthopedic procedures. Heparin is also used fordiagnostic and therapeutic interventional radiologic procedures. Akers' test isable to identify, almost instantly, patients at risk for developing HITTS as aresult of administering of heparin. This is particularly crucial in cases ofemergency surgery. Patients identified by the test as being at risk can beprescribed alternative drugs in order to avoid, potentially, fatal reactions toheparin.Cholesterol TestsBlood cholesterol consists of HDL cholesterol (often called "good cholesterol")and LDL cholesterol (often called "bad cholesterol"). The risk of heart diseaseis related to HDL levels, total cholesterol levels, and other risk factors. TheAkers Biosciences Tri-Cholesterol Test Kit is the only FDA-approved rapid assaythat provides a complete cholesterol profile of the patient, withsemi-quantitative determinations of high-density lipoprotein (HDL) cholesterol,low-density lipoprotein (LDL) cholesterol, and total cholesterol levels inwhole blood obtained from a finger stick. The test is designed for routinemonitoring of cholesterol levels right in a physician's office or directly athome.Dr. Raymond Akers, Chief Executive, Akers Biosciences, Inc. commented,"We are now enjoying very encouraging levels of sales for many of our productsin the United States and other parts of the world and I am delighted to beembarking upon an aggressive marketing and sales drive in the UK. As is thecase in the US, many of our products will be completely unique in the UK,enabling crucial tests to be performed rapidly and accurately. There is agrowing need for tests for alcohol levels and use of drugs of abuse all overthe world. Our tests in this area will enable people, particularly in thetransport and education industries to identify situations of abuse instantly.As for our PIFA Heparin PF-4 test, we believe this test will help save lives inthe UK. In addition, the medical industry can save millions of pounds inheparin-related law suits of patients who have suffered symptoms of a drugwhose prescription could have been avoided through identification of risk withour test and the prescription of an alternative."Dr. Raymond AkersChief Executive, Akers Biosciences, Inc.Tel. 020 7917 9476Barry ParkerChief Executive, Advanced Rapid Diagnostics LimitedTel. 0161 792 1112Ben SimonsHansard CommunicationsTel. 020 7245 1100ENDAKERS BIOSCIENCES INC
Date   Source Headline
8th May 20181:00 pmRNSHolding(s) in Company
27th Apr 20182:05 pmRNSSecond Price Monitoring Extn
27th Apr 20182:00 pmRNSPrice Monitoring Extension
26th Apr 20187:00 amRNSDirectorate Change
13th Apr 20185:45 pmRNSIssue of Equity
12th Apr 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
6th Apr 20184:30 pmRNSIssue of Equity
3rd Apr 201811:05 amRNSFinal Results
28th Mar 20184:20 pmRNSNotice of Fiscal Year 2017 Earnings - Rescheduled
26th Mar 20187:01 amRNSDistribution Agreement with Diagnostica Stago
26th Mar 20187:00 amRNSIssue of Equity
16th Mar 20184:00 pmRNSIssue of Equity
15th Mar 20185:30 pmRNSNotice of Results
9th Mar 20186:29 pmRNSIssue of Equity
2nd Mar 20185:15 pmRNSIssue of Equity
16th Feb 20185:45 pmRNSIssue of Equity
14th Feb 20185:30 pmRNSHoldings in Company
9th Feb 20186:00 pmRNSIssue of Equity
2nd Feb 20184:42 pmRNSIssue of Equity
26th Jan 20187:00 amRNSIssue of Equity
22nd Jan 20184:27 pmRNSHoldings in Company
19th Jan 20183:35 pmRNSIssue of Equity
16th Jan 20186:20 pmRNSIssue of Equity
15th Jan 20187:00 amRNSUpdate RE Admission of Shares
12th Jan 20187:00 amRNSIssue of Equity
5th Jan 20186:29 pmRNSIssue of Equity
4th Jan 20184:45 pmRNSHoldings in Company
27th Dec 20172:01 pmRNSIssue of Equity
22nd Dec 20177:00 amRNSClosing of Public Offering
19th Dec 20177:00 amRNSIssue of Equity
18th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
15th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
14th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
11th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
8th Dec 20173:30 pmRNSFurther IP Protection for Akers Wellness Line
1st Dec 20172:00 pmRNSForm 8K Filing
27th Nov 20177:00 amRNSForm S-1 Registration Statement
15th Nov 20177:00 amRNS3rd Quarter Results
14th Nov 20177:00 amRNSNew UK Channel for Rapid Alcohol Breathalyzer
13th Nov 20172:00 pmRNSNotice of Results
8th Nov 20171:59 pmRNSIssue of Equity
20th Oct 20177:00 amRNSPDMR Shareholding and Issue of Equity
19th Oct 20174:20 pmRNSDirector/PDMR Shareholding
13th Oct 20172:35 pmRNSWarrant Amendment and Exercise
7th Sep 20177:00 amRNSAppointment of U.S. VP of Sales & Distribution
15th Aug 20177:00 amRNSHalf-year Report
11th Aug 20177:00 amRNSIssue of Equity
8th Aug 20177:00 amRNSResult of AGM
3rd Aug 20174:30 pmRNSTrading Update and Notice of Q2 Results
20th Jul 201711:10 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.